LINC00957 Acted as Prognostic Marker Was Associated With Fluorouracil Resistance in Human Colorectal Cancer

Zhang, Li Hua; Li, Long Hai; Zhang, Peng Fei; Cai, Yan; Hua, Dong

doi:10.3389/fonc.2019.00776

Cited by 22 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identification of Prognostic EMT-Related lncRNA colorectal cancer patients (18); LINC02532 was demonstrated to act as an oncogene in gastric cancer (GC) and promoted the GC cell proliferation, migration, and invasion (19); DOCK9-DT was revealed to play a protective role in the prognosis of thyroid carcinoma (20); THUMPD3-AS1 regulated non-small cell lung cancer cell self-renewal via the expression of miR-543 and ONECUT2, and THUMPD3-AS1 can serve as a potential biomarker or therapeutic target in non-small cell lung cancer (21). Additionally, APCDD1L-DT exhibits a significant prognostic value in lung squamous cell carcinoma (LUSC) and can independently predict the overall survival in LUSC patients (22).…”

Section: Discussionmentioning

confidence: 99%

Identification of Epithelial–Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma

Zhong

Zhang²,

Huang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Epithelial–mesenchymal transition (EMT), a reversible cellular program, is critically important in tumor progression and is regulated by a family of transcription factors, induction factors, and an array of signaling pathway genes. The prognostic role and biological functions of EMT-related lncRNAs in ccRCC are largely unknown. In the present study, we analyzed the gene expression data and clinical information retrieved from The Cancer Genome Atlas (TCGA) database (N=512) and International Cancer Genome Consortium (ICGC) database (N=90) which served as training and external validation dataset, respectively. Then, we constructed an EMT-related lncRNA risk signature based on the comprehensive analysis of the EMT-related lncRNA expression data and clinical information. The Kaplan-Meier curve analysis revealed that patients in the low-risk and high-risk groups exhibited significant divergence in the overall survival (OS) and disease-free survival (DFS) of ccRCC, as was confirmed in the validation dataset. The Cox regression analysis of the clinical factors and risk signature in the OS and DFS demonstrated that the risk signature can be utilized as an independent prognostic predictor. Moreover, we developed an individualized prognosis prediction model relying on the nomogram and receive operator curve (ROC) analysis based on the independent factors. The Gene Set Enrichment Analysis (GSEA) indicated that patients in the low-risk group were associated with adherens junction, focal adhesion, MAPK signaling pathway, pathways in cancer, and renal cell carcinoma pathway. In addition, we identified three robust subtypes (named C1, C2 and C3) of ccRCC with distinct clinical characteristics and prognostic role in the TCGA dataset and ICGC dataset. Among them, C1 was associated with a better survival outcome, whereas C2 and C3 was associated with a worse survival outcome and have more advanced-stage patients. Moreover, C2 was more likely to respond to immunotherapy and was sensitive to chemo drugs, this may provide insights to clinicians to develop an individualized treatment. Collectively, this work developed a reliable EMT-related lncRNA risk signature that can independently predict the OS and DFS of ccRCC. Besides, we identified three stable molecular subtypes based on the EMT-related lncRNA expression, which may comprehensively be vital in elucidating the underlying molecular mechanism of ccRCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Epithelial–Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma

Zhong

Zhang²,

Huang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…15 However, nearly 50% of colorectal cancer patients showed no response to 5-Fu, and more and more studies reported that fluorouracil resistance led to failure of CRC treatment. [16][17][18] But the mechanism is not clear. Therefore, biomarkers predicting the efficacy of fluorouracil are urgently needed in CRC treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

Zhu

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: Although the survival rate of colorectal cancer (CRC) patients can be improved by surgery, radiotherapy, and chemotherapy, the resistance to 5-fluorouracil (5-Fu) affects the effect of chemotherapy and the prognosis of patients. An increasing number of studies showed that 5-Fu resistance was the main reason for the failure of colorectal cancer treatment. The poor prognosis of colorectal cancer greatly harms people's health. This study aimed to clarify the correlation between cyclin-dependent kinase 1 (CDK1) and 5-Fu-induced tumor resistance. Materials and Methods: Cell proliferation and invasion experiments showed that downregulation of CDK1 inhibited fluorouracil-resistant CRC cell proliferation. The expression level of CDK1 was detected in 5-Fu-resistant CRC cells in vitro. Tumor growth was inhibited by down-regulation of CDK1 in tumor xenograft mouse models. Results: We found that CDK1 was highly expressed in tumor tissues, especially in fluorouracil-resistant tissues. We also confirmed that the differential expression of 5-Fu in tumor tissues was related to tumor site, lymph node metastasis and stage. CDK1 promoted migration, invasion and inhibited apoptosis in 5-Fu-resistant CRC cells. Down-regulation of CDK1 inhibited fluorouracil-resistant CRC cell proliferation and tumorigenesis in vivo. Conclusion: High expression of CDK1 may lead to poor clinical prognosis, and inhibition of CDK1 enhances 5-Fu sensitivity in CRC. Our research suggested that CDK1 may be used to predict 5-Fu efficacy and as a therapeutic target for CRC.

show abstract

“…The long non-coding RNA00957 (LINC00957) was demonstrated to be involved in tumor progression, and Zhang et al [39] . found that the expression levels of LINC00957 were significantly associated with advanced TNM stage, poor chemotherapy outcomes, and worse prognosis.…”

Section: Discussionmentioning

confidence: 99%

Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma

Zhang

Liu

Kong

2021

Journal of Bone Oncology

View full text Add to dashboard Cite

Highlights Nomograms were constructed to provide accurate and individualized survival prediction for recurrence in osteosarcoma patients. The current study provides novel potential of seven RNAs (LINC00957, METL1, CA9, B3GALT4, ALDH1A1, LAMB3 and ITGB4) candidate prognostic biomarkers for recurrence in osteosarcoma patients. LncRNA LINC00957 may regulated the recurrence of osteosarcoma by pathways in cancer.

show abstract

LINC00957 Acted as Prognostic Marker Was Associated With Fluorouracil Resistance in Human Colorectal Cancer

Cited by 22 publications

References 34 publications

Identification of Epithelial–Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma

Identification of Epithelial–Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma

<p>Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer</p>

Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma

Contact Info

Product

Resources

About